Over the past 10 years several effective new therapies have been developed for patients with advanced melanoma. Since 2010, the primary endpoint of every major phase III trial in this setting has been met, revolutionizing the treatment options and survival for patients with unresectable advanced melanoma. With increasing numbers of patients experiencing durable remissions with these agents, even without continuing therapy, the issue of melanoma survival care becomes of relevance to more patients than ever before.
Originele taal-2English
Pagina's (van-tot)3-10
TijdschriftBelgian Journal of Medical Oncology
VolumeSpecial edition
StatusPublished - jan 2018


Duik in de onderzoeksthema's van 'Long-term survival in immunotherapy treated patients with unresectable advanced melanoma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit